Senior PMDD Key Opinion Leaders who co-authored the publication with Asarina Pharma CSO Prof Torbjörn Bäckström (Uneaå University, Sweden):
Prof.Nick Panay Imperial College London
Prof. Shaughn O’Brien Royal Stoke University Hospital, UK
Prof. C. Neill Epperson Dept. Psychiatry, University of Colorado
Prof. Marie Bixo Umeå University, Sweden
Dr. Angelica Lindén Hirschberg, Karolinska University Hospital, Stockholm, Sweden.
Asarina Pharma CEO Peter Nordkild:
“These findings would be valuable to any larger pharma partner wishing to pursue future PMDD studies. We have been very clear that we do not intend to continue clinical development of Sepranolone for PMDD by ourselves – a study needed to further corroborate these findings would realistically involve at least six months of therapy and likely several hundred patients – which is clearly beyond our current capabilities.
“Nevertheless, these data are exciting, and represent a promising body of evidence when it comes to a pharmaceutical treatment for PMDD.
“They further clearly point towards allopregnanolone’s role as a key factor in triggering highly disruptive, mood-altering symptoms, including our current focus areas of Tourette and OCD – and confirm our confidence in Sepranolone as an important and effective modulator of allopregnanolone.”